已发表论文

CART 细胞治疗前列腺癌:现状和承诺

 

Authors Yu H, Pan J, Guo Z, Yang C, Mao L

Received 28 August 2018

Accepted for publication 22 November 2018

Published 3 January 2019 Volume 2019:12 Pages 391—395

DOI https://doi.org/10.2147/OTT.S185556

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Sanjay Singh

Abstract: In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
Keywords: prostate cancer, CAR-T cells, adoptive immunotherapy, review




Figure 1 Diagram of the structures of CARs.